EnteroBiotix Initiates Phase 2 Study of EBX-102-02 in Patients with Irritable Bowel Syndrome (IBS)
Glasgow, Scotland – 3 April 2023. EnteroBiotix Limited, a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, today announced that the first patient has been dosed in a multi-centre randomised double-blind placebo controlled clinical trial designed to evaluate EBX-102-02 for the treatment of IBS.
